Larimar Therapeutics, Inc. LRMR

LRMR Company Overview

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing protein replacement therapies for rare genetic diseases. The company operates within the biotechnology and life sciences industry, with a primary emphasis on neurological and neuromuscular disorders. Larimar’s core mission is to address diseases caused by deficiencies in mitochondrial or intracellular proteins that are not adequately treated by existing therapies.

The company’s principal product candidate is CTI-1601 (nomlabofusp), a recombinant human frataxin protein conjugated to a cell-penetrating peptide, being developed for the treatment of Friedreich’s ataxia, a rare, inherited neurodegenerative disease. Larimar’s strategic positioning centers on its proprietary intracellular delivery platform designed to enable systemic protein replacement, which differentiates it from gene therapy and small-molecule approaches. The company was originally founded as Tisone Therapeutics and rebranded as Larimar Therapeutics, Inc. in 2018 following a strategic refocus on rare disease protein therapeutics.